Balanced mineralization in the arterial system: Possible role of osteoclastogenesis/osteoblastogenesis in abdominal aortic aneurysm and stenotic disease

Circulation Journal

Volumn 76, Issue 12, 2012, Pages 2732-2737

  Yamanouchi, Dai ^a   Takei, Yuichiro ^a   Komori, Kimihiro ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aneurysms; Aorta; Calcium

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CALCIUM CHLORIDE; CALCIUM PHOSPHATE; INTERLEUKIN 6; OSTEOCALCIN; OSTEOPONTIN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGING; AORTA ANEURYSM; AORTA STENOSIS; ARTERY CALCIFICATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; REVIEW; UPREGULATION;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; BONE DENSITY; CONSTRICTION, PATHOLOGIC; DIABETES MELLITUS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

EID: 84870501462     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1240     Document Type: Review

References (83)

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening: Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126: 441-449.
2. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-1387.
3. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-1428.
4. Halliday A, Mansfeld A, Marro J, Peto C, Peto R, Potter J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomised controlled trial. Lancet 2004; 363: 1491-1502.
5. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty study (CAVATAS): A randomised trial. Lancet 2001; 357: 1729-1737.
6. O'Sullivan JP. The coroner's necropsy in sudden death: An underused source of epidemiological information. J Clin Pathol 1996; 49: 737-740.
7. Kent KC, Zwolak RM, Jaff MR, Hollenbeck ST, Thompson RW, Schermerhorn ML, et al. Screening for abdominal aortic aneurysm: A consensus statement. J Vasc Surg 2004; 39: 267-269.
8. Li J, Flammer AJ, Nelson RE, Gulati R, Friedman PA, Thomas RJ, et al. Normal vascular function as a prerequisite for the absence of coronary calcifcation in patients free of cardiovascular disease and diabetes. Circ J 2012; 76: 2705-2710.
9. Witteman JC, Kok FJ, van Saase JL, Valkenburg HA. Aortic calcifcation as a predictor of cardiovascular mortality. Lancet 1986; 2: 1120-1122.
10. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, et al. Molecular, endocrine, and genetic mechanisms of arterial calcifcation. Endocr Rev 2004; 25: 629-672.
11. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH. Medial arterial calcifcation and its association with mortality and complications of diabetes. Diabetologia 1988; 31: 16-23.
12. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcifcation: A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978-983.
13. Amann K. Media calcifcation and intima calcifcation are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
14. Hassan NA, D'Orsi ET, D'Orsi CJ, O'Neill WC. The risk for medial arterial calcifcation in CKD. Clin J Am Soc Nephrol 2012; 7: 275-279.
15. Kawai H, Sarai M, Motoyama S, Harigaya H, Ito H, Sanda Y, et al. Coronary plaque characteristics in patients with mild chronic kidney disease: Analysis by 320-row area detector computed tomography. Circ J 2012; 76: 1436-1441.
16. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H. Vascular calcifcation and osteoporosis: From clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259.
17. Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L. Chronic kidney disease and diabetes. Maturitas 2012; 71: 94-103.
18. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: A growing concern. Kidney Int 2008; 74: 721-731.
19. Hamann C, Kirschner S, Gunther KP, Hofbauer LC. Bone, sweet bone: Osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol 2012; 8: 297-305.
20. Abdulameer SA, Sulaiman SA, Hassali MA, Subramaniam K, Sahib MN. Osteoporosis and type 2 diabetes mellitus: What do we know, and what we can do? Patient Prefer Adherence 2012; 6: 435-448.
21. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethyl-arginine in nondiabetic chronic kidney disease patients. Metabolism 2009; 58: 1624-1628.
22. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxf) 2003; 42: 1242-1246.
23. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glycation end-product Ne-carboxymethyl-lysine accelerates progression of atherosclerotic calcifcation in diabetes. Atherosclerosis 2012; 221: 387-396.
24. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcifcation of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-580.
25. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, et al. RANKL increases vascular smooth muscle cell calcifcation through a RANK-BMP4-dependent pathway. Circ Res 2009; 104: 1041-1048.
26. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcifcation in diabetic Charcot neuroarthropathy. Diabetes 2011; 60: 2187-2196.
27. Yuan LQ, Zhu JH, Wang HW, Liang QH, Xie H, Wu XP, et al. RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011; 6: e29037.
28. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-defcient mice develop early onset osteoporosis and arterial calcifcation. Genes Dev 1998; 12: 1260-1268.
29. Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K. Low serum osteoprotegerin levels in normoalbumin-uric type 1 diabetes mellitus. Acta Diabetol 2010; 47: 105-110.
30. New SE, Aikawa E. Molecular imaging insights into early infammatory stages of arterial and aortic valve calcifcation. Circ Res 2011; 108: 1381-1391.
31. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994; 93: 2106-2113.
32. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcifcation of vascular cells via the camp pathway. Circulation 2000; 102: 2636-2642.
33. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer LL, et al. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 2005; 96: 398-400.
34. Bostrom K. Insights into the mechanism of vascular calcifcation. Am J Cardiol 2001; 88: 20E-22E.
35. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcifcation. Crit Rev Eukaryot Gene Expr 2000; 10: 151-158.
36. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809.
37. Johnson RC, Leopold JA, Loscalzo J. Vascular calcifcation: Patho-biological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059.
38. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011; 109: 564-577.
39. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
40. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-771.
41. Komori T. Regulation of bone development and maintenance by Runx2. Front Biosci 2008; 13: 898-903.
42. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, et al. Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011; 31: 1387-1396.
43. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. Phosphate feeding induces arterial medial calcifcation in ure-mic mice: Role of serum phosphorus, fbroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
44. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, et al. Oxidative stress induces vascular calcifcation through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319-15327.
45. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H. Dexamethasone enhances in vitro vascular calcifcation by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 2112-2118.
46. Li X, Yang HY, Giachelli CM. Bmp-2 promotes phosphate uptake, phenotypic modulation, and calcifcation of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-277.
47. Sutra T, Morena M, Bargnoux AS, Caporiccio B, Canaud B, Cristol JP. Superoxide production: A procalcifying cell signalling event in osteoblastic differentiation of vascular smooth muscle cells exposed to calcifcation media. Free Radic Res 2008; 42: 789-797.
48. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcifcation. Circ Res 2000; 87: E10-E17.
49. Al-Aly Z. Phosphate, oxidative stress, and nuclear factor-κB activation in vascular calcifcation. Kidney Int 2011; 79: 1044-1047.
50. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, et al. Smooth muscle cell-specifc Runx2 defciency inhibits vascular calcifcation. Circ Res 2012; 111: 543-552.
51. Bostrom K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic pro-tein-2 in C3H10T1/2 cells. J Biol Chem 2001; 276: 14044-14052.
52. Yao Y, Zebboudj AF, Shao E, Perez M, Bostrom K. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem 2006; 281: 33921-33930.
53. Meier M, Weng LP, Alexandrakis E, Ruschoff J, Goeckenjan G. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001; 17: 566-569.
54. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcifcation of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
55. Yavropoulou MP, Yovos JG. Osteoclastogenesis: Current knowledge and future perspectives. J Musculoskelet Neuronal Interact 2008; 8: 204-216.
56. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption patho-physiology. Cytokine Growth Factor Rev 2004; 15: 49-60.
57. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular cal-cifcation: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26: 1423-1430.
58. Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch 1998; 433: 559-565.
59. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, et al. Rationale for the role of osteoclast-like cells in arterial calcifcation. FASEB J 2002; 16: 577-582.
60. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 2003; 61: 504-513.
61. Ko T, Gatz MG, Reisz GR. Congenital unilateral absence of a pulmonary artery: A report of two adult cases. Am Rev Respir Dis 1990; 141: 795-798.
62. Lindeman JH, Abdul-Hussien H, Schaapherder AF, Van Bockel JH, Von der Thusen JH, Roelen DL, et al. Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin Sci (Lond) 2008; 114: 687-697.
63. Silverman SL. Sclerostin. J Osteoporos 2010; 2010: 941419.
64. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-286.
65. Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 2008; 27: 589-599.
66. Gertz SD, Kurgan A, Eisenberg D. Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride in vivo. J Clin Invest 1988; 81: 649-656.
67. Freestone T, Turner RJ, Higman DJ, Lever MJ, Powell JT. Infuence of hypercholesterolemia and adventitial infammation on the development of aortic aneurysm in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 10-17.
68. Chiou AC, Chiu B, Pearce WH. Murine aortic aneurysm produced by periarterial application of calcium chloride. J Surg Res 2001; 99: 371-376.
69. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-632.
70. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11: 1330-1338.
71. Bostrom K, Watson KE, Stanford WP, Demer LL. Atherosclerotic calcifcation: Relation to developmental osteogenesis. Am J Cardiol 1995; 75: 88B-91B.
72. Weissen-Plenz G, Nitschke Y, Rutsch F. Mechanisms of arterial cal-cifcation: Spotlight on the inhibitors. Adv Clin Chem 2008; 46: 263-293.
73. Villa-Bellosta R, Sorribas V. Calcium phosphate deposition with normal phosphate concentration: Role of pyrophosphate. Circ J 2011; 75: 2705-2710.
74. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: A potential mechanism in atherosclerotic plaque destabilization. Circ Res 2008; 103: e28-e34.
75. Pazar B, Ea HK, Narayan S, Kolly L, Bagnoud N, Chobaz V, et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1 β secretion through the NLRP3 infammasome in vitro. J Immunol 2011; 186: 2495-2502.
76. Yamanouchi D, Morgan S, Stair C, Seedial S, Lengfeld J, Kent KC, et al. Accelerated aneurysmal dilation associated with apoptosis and infammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. J Vasc Surg 2012; 56: 455-461.
77. Yamanouchi D, Stair C, Morgan S, Kent KC. Osteoclastogenesis as a novel therapeutic target for abdominal aortic aneurysm. Circulation 2011; 124: A9593
78. Abdul-Hussien H, Hanemaaijer R, Kleemann R, Verhaaren BF, van Bockel JH, Lindeman JH. The pathophysiology of abdominal aortic aneurysm growth: Corresponding and discordant infammatory and proteolytic processes in abdominal aortic and popliteal artery aneu-rysms. J Vasc Surg 2010; 51: 1479-1487.
79. Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H. Whole genome expression profling reveals a signif-cant role for immune function in human abdominal aortic aneurysms. BMC Genomics 2007; 8: 237.
80. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD. The pro-infammatory and chemotactic cytokine microenviron-ment of the abdominal aortic aneurysm wall: A protein array study. J Vasc Surg 2007; 45: 574-580.
81. Urbonavicius S, Lindholt JS, Delbosc S, Urbonaviciene G, Henneberg EW, Vorum H, et al. Proteins associated with the size and expansion rate of the abdominal aortic aneurysm wall as identifed by proteomic analysis. Interact Cardiovasc Thorac Surg 2010; 11: 433-441.
82. Choke E, Cockerill GW, Laing K, Dawson J, Wilson WR, Loftus IM, et al. Whole genome-expression profling reveals a role for immune and infammatory response in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2009; 37: 305-310.
83. Choke E, Thompson MM, Jones A, Torsney E, Dawson J, Laing K, et al. Gene expression profle of abdominal aortic aneurysm rupture. Ann N Y Acad Sci 2006; 1085: 311-314.